Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Deferred Tax (2016 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Deferred Tax for 10 consecutive years, with $16.9 million as the latest value for Q2 2025.

  • Quarterly Long-Term Deferred Tax rose 11.32% to $16.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $16.9 million through Apr 2025, up 11.32% year-over-year, with the annual reading at $16.9 million for FY2025, 11.32% up from the prior year.
  • Long-Term Deferred Tax for Q2 2025 was $16.9 million at PharmaCyte Biotech, up from $15.2 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $16.9 million in Q2 2025, with the low at $15.2 million in Q2 2024.